HER2 mutation as an emerging target in advanced breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• HER2 (Human Epidermal growth factor Receptor 2) activating mutations are key drivers in various cancers.
• In breast cancer, these mutations are found in HER2-nonamplified metastatic disease and represent an alternative to HER2 gene amplification.
• Acquired HER2 alterations emerge during treatment, contributing to therapy resistance.

Purpose of the Study:

• To review the structural organization and historical significance of the HER2 oncogene in breast cancer.
• To summarize the frequency, functional relevance, and role of HER2 mutations in therapeutic resistance.
• To present ongoing clinical trials investigating novel therapies for HER2-mutant breast cancer.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of HER2 oncogene structure and mutation landscape.
• Compilation of ongoing clinical trials for HER2-mutant breast cancer.

Main Results:

• HER2 mutations confer constitutive activation, acting as oncogenic drivers.
• These mutations are increasingly recognized as a mechanism of resistance to endocrine and HER2-targeted therapies.
• Numerous clinical trials are evaluating HER2-targeted drugs for HER2-mutant breast cancer patients.

Conclusions:

• HER2 mutations are critical therapeutic targets in breast cancer, particularly in resistant disease.
• Understanding HER2 mutation roles is vital for developing effective treatment strategies.
• Ongoing trials offer hope for patients with HER2-mutant breast cancer, addressing challenges in targeted therapy.